BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21883822)

  • 1. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
    van Poppel H; Haese A; Graefen M; de la Taille A; Irani J; de Reijke T; Remzi M; Marberger M
    BJU Int; 2012 Feb; 109(3):360-6. PubMed ID: 21883822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.
    Durand X; Xylinas E; Radulescu C; Haus-Cheymol R; Moutereau S; Ploussard G; Forgues A; Robert G; Vacherot F; Loric S; Allory Y; Ruffion A; de la Taille A
    BJU Int; 2012 Jul; 110(1):43-9. PubMed ID: 22221521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
    J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
    De Luca S; Passera R; Milillo A; Coda R; Randone DF
    BJU Int; 2012 Dec; 110(11 Pt B):E778-82. PubMed ID: 23116408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    PerdonĂ  S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
    Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
    BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer.
    Komai Y; Kawakami S; Numao N; Fujii Y; Saito K; Kubo Y; Koga F; Kumagai J; Yamamoto S; Yonese J; Ishikawa Y; Fukui I; Kihara K
    BJU Int; 2012 Dec; 110(11 Pt B):E564-9. PubMed ID: 22757686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.